neutralising αccl2 mab (Bio X Cell)
Bio X Cell is a verified supplier 
Bio X Cell manufactures this product 
90
Structured Review
Bio X Cell
neutralising αccl2 mab
Neutralising αccl2 Mab, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/neutralising+%CE%B1ccl2+mab/%CE%B1ccl2+antibody/pmc08292576-39-9-18
Average 90 stars, based on 1 article reviews
Neutralising αccl2 Mab, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/neutralising+%CE%B1ccl2+mab/%CE%B1ccl2+antibody/pmc08292576-39-9-18
Average 90 stars, based on 1 article reviews
neutralising αccl2 mab - by Bioz Stars,
2026-09
90/100 stars
Images
1) Product Images from "Cross-talk between the gut microbiota and monocyte-like macrophages mediates an inflammatory response to promote colitis-associated tumourigenesis"
Article Title: Cross-talk between the gut microbiota and monocyte-like macrophages mediates an inflammatory response to promote colitis-associated tumourigenesis
Journal: Gut
doi: 10.1136/gutjnl-2020-320777
Figure Legend Snippet: Colonic MLM accumulation is controlled by CCL2/CCR2. (A) Expression of chemokine receptors in each macrophage subset in mice of 9 weeks after AOM-DSS induction (n=4–9). *p<0.05; ***p<0.001; ****p<0.0001, two-way ANOVA. (B) Normalised gene expression for chemokine and chemokine receptor in the colon throughout disease progression (n=6 for each time point). Data were represented as the ratio to baseline. Two-way ANOVA. (C, D) Effect of CCR2 inhibitor (C) or αCCL2 (D) on MLM accumulation and colon tumourigenesis (scale bar, 5 mm; n=6–9 per group). *p<0.05; **p<0.01, Student’s t-test. AOM-DSS, azoxymethane-dextran sodium sulfate; ANOVA, analysis of variance; CCR2, C-C chemokine receptor type 2; MLM, monocyte-like macrophage.
Techniques Used: Expressing, Gene Expression, Biomarker Discovery
Figure Legend Snippet: TLR4 activation mediates CCL2 upregulation in CECs, MLM accumulation and tumour formation. (A) Representative images of tumours in the colon of mice treated with H 2 O or ABX (scale bar, 5 mm). The right panel indicates quantification of tumours in mice (AOM-DSS wk9: n=6; AOM-DSS +ABX wk9: n=10). ****p<0.0001, Student’s t-test. (B) CCL2 expression in colon tissues (AOM-DSS wk9: n=8; AOM-DSS +ABX wk9: n=10). *p<0.05, Student’s t-test. (C) CD206 expression in colonic macrophages (AOM-DSS wk9: n=14; AOM-DSS +ABX wk9: n=10). ****p<0.0001, Student’s t-test. (D) Colonic MLMs in mice treated with H 2 O or ABX (AOM-DSS wk9: n=6; AOM-DSS +ABX wk9: n=8). **p<0.01, Student’s t-test. (E, F) Normalised gene expression of inflammation-related genes in colon tissues (E), and Ki-67 expression in CECs (F) from vehicle or ABX-treated AOM-DSS wk9 mice (n=5–8 per group). *p<0.05; ***p<0.001, Student’s t-test. (G) Intracellular CCL2 levels in different cell types as assessed by flow cytometry (AOM-DSS wk9: n=6; AOM-DSS +ABX wk9: n=6). ****p<0.0001, two-way ANOVA. (H) CCL2 expression in CECs isolated from mice treated with H 2 O or ABX (AOM-DSS wk9: n=9; AOM-DSS +ABX wk9: n=7). *p<0.05, Student’s t-test. (I) Immunofluorescence staining of CCL2 and EpCAM in colon sections from mice treated with H 2 O or ABX. (J) PRR-related gene expression in H 2 O- or ABX-treated mice (AOM-DSS wk9: n=7; AOM-DSS +ABX wk9: n=7). **p<0.01, ****p<0.0001, two-way ANOVA. (K) Isolated CECs from normal mice were cultured in the presence of faecal extracts, or a combination of TLR4 inhibitor. CCL2 production was measured by flow cytometry (n=10 for each group). ****p<0.0001, one-way ANOVA. (L) Faecal LPS levels (AOM-DSS wk9: n=12; AOM-DSS +ABX wk9: n=6). **p<0.01, Student’s t-test. (M) ABX-pretreated AOM-DSS mice were additionally administered with rCCL2 or TLR4 ligand or vehicle. Colonic MLMs in mice (9 weeks after AOM-DSS induction) were quantified by flow cytometry (n=8–11 for each group). *p<0.05, **p<0.01, one-way ANOVA. (N–O) ABX-treated AOM-DSS mice receiving rCCL2 or TLR4 ligand. In some experiments, TLR4 ligand-treated mice also received αCCL2 or CCR2 inhibitor. Representative images (N) and quantification (O) of tumours in different treatments (scale bar, 5 mm; n=8–11 for each group, 9 weeks after AOM-DSS induction). *p<0.05, one-way ANOVA. ABX, antibiotic; AOM-DSS, azoxymethane-dextran sodium sulfate; ANOVA, analysis of variance; CCR2, C-C chemokine receptor type 2; CECs, colonic epithelial cells; IL1β, interleukin 1β; LPS, lipopolysaccharide; MLM, monocyte-like macrophage; TLR4, Toll-like receptor 4; TNF-α, tumour necrosis factor α.
Techniques Used: Activation Assay, Expressing, Gene Expression, Flow Cytometry, Isolation, Immunofluorescence, Staining, Cell Culture
Figure Legend Snippet: Diverse effects of stage-specific microbiota on MLM accumulation and tumourigenesis. (A) The proportion of gram-negative bacteria within microbiomes of stools from mice at different time points, as predicted by BugBase (n=4 for each time point). (B) Mice pretreated with ABX for 4 weeks were (i) repopulated with faeces from healthy baseline mice, (ii) repopulated with faeces from 3 week, 6 week or 9 week AOM-DSS mice. Mice were then induced with AOM-DSS. TLR4 and CCL2 levels in CECs, and colonic MLM levels were determined by flow cytometry (n=7–11 for each group). (C, D) The ABX- or vehicle-pretreated mice were repopulated with faeces from different stages of tumourigenesis, or sham-repopulated. Mice were subsequently induced with AOM-DSS. Representative images (C) and quantitative analysis (D) of tumours in different treatments (scale bar, 5 mm; n=7–12 for each group). Data are represented as mean±SEM; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, one-way ANOVA. (E, F) Species differences in patients with ulcerative colitis (UC) (E) or colorectal cancer (CRC) (F) compared with healthy donors. Species name in red: known gram-negative bacteria. Runs indicate objects containing sequencing run data files, and each dot in plots represents one related run. ‘Related runs’ refer to the total number of runs that are detected positive for specific bacterial species. Multiple t-test with two-stage step-up method of Benjamini, Krieger and Yekutieli. ABX, antibiotic; AOM-DSS, azoxymethane-dextran sodium sulfate; ANOVA, analysis of variance; CECs, colonic epithelial cells; MLM, monocyte-like macrophage.
Techniques Used: Bacteria, Flow Cytometry, Sequencing
Figure Legend Snippet: TLR4 ligands derived from microbiota induce the accumulation and activation of MLMs. (A) Functional profiling of microbiome throughout disease progression (n=4 for each time point). (B) Faecal LPS levels (AOM-DSS baseline/wk3/wk6/wk9: n=8/7/6/12). (C) CCL2 expression in CECs isolated from normal mice treated with multiple concentrations of LPS for 6 hours. control: n=10; n=3 for each group of LPS treatment. (D) Intracellular CCL2 levels in CECs from AOM-DSS mice treated with LPS, or a combination of TLR4 inhibitor (n=5–6 for each group, 9 weeks after AOM-DSS induction). (E) Mice were treated with 2.5% DSS for 7 days. Colonic MLMs were sorted by flow cytometry on day seven and then cultured in the presence of LPS, or a combination of TLR4/COX-2 inhibitor for 36 hours. MACS-sorted splenic CD4 + cells from normal mice were cultured with supernatant from MLM-drug cocultures under Th17 polarising conditions. As indicated, antimouse IL-1β was additionally added (n=8–15 for each group). (F–H) AOM-DSS mice with LPS or vehicle treatment. In some experiments, LPS (2 mg/kg)-treated mice were additionally administered with a TLR4 or COX-2 inhibitor. (F) Pro-IL1β + MLMs, IL-17A + CD4 + cells and Ki-67 + CECs in mice (9 weeks after AOM-DSS induction) were determined by flow cytometry (n=6–8 for each group). Representative images (G) and quantitative analysis (H) of tumours (scale bar, 5 mm; n=4–20 for each group). Data are represented as mean±SEM; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, one-way ANOVA. A/D, AOM-DSS. ABX, antibiotic; AOM-DSS, azoxymethane-dextran sodium sulfate; ANOVA, analysis of variance; CCR2, C-C chemokine receptor type 2; CECs, colonic epithelial cells; IL1β, interleukin 1β; LPS, lipopolysaccharide; MLM, monocyte-like macrophage; Th17, interleukin-17-producing T-helper; TLR4, Toll-like receptor 4.
Techniques Used: Derivative Assay, Activation Assay, Functional Assay, Biomarker Discovery, Expressing, Isolation, Control, Flow Cytometry, Cell Culture
Related Articles
Expressing:Article Title: Cross-talk between the gut microbiota and monocyte-like macrophages mediates an inflammatory response to promote colitis-associated tumourigenesis Article Snippet: In select experiments, mice were treated with a neutralising Gene Expression:Article Title: Cross-talk between the gut microbiota and monocyte-like macrophages mediates an inflammatory response to promote colitis-associated tumourigenesis Article Snippet: In select experiments, mice were treated with a neutralising Biomarker Discovery:Article Title: Cross-talk between the gut microbiota and monocyte-like macrophages mediates an inflammatory response to promote colitis-associated tumourigenesis Article Snippet: In select experiments, mice were treated with a neutralising Activation Assay:Article Title: Cross-talk between the gut microbiota and monocyte-like macrophages mediates an inflammatory response to promote colitis-associated tumourigenesis Article Snippet: In select experiments, mice were treated with a neutralising Flow Cytometry:Article Title: Cross-talk between the gut microbiota and monocyte-like macrophages mediates an inflammatory response to promote colitis-associated tumourigenesis Article Snippet: In select experiments, mice were treated with a neutralising Isolation:Article Title: Cross-talk between the gut microbiota and monocyte-like macrophages mediates an inflammatory response to promote colitis-associated tumourigenesis Article Snippet: In select experiments, mice were treated with a neutralising Immunofluorescence:Article Title: Cross-talk between the gut microbiota and monocyte-like macrophages mediates an inflammatory response to promote colitis-associated tumourigenesis Article Snippet: In select experiments, mice were treated with a neutralising Staining:Article Title: Cross-talk between the gut microbiota and monocyte-like macrophages mediates an inflammatory response to promote colitis-associated tumourigenesis Article Snippet: In select experiments, mice were treated with a neutralising Cell Culture:Article Title: Cross-talk between the gut microbiota and monocyte-like macrophages mediates an inflammatory response to promote colitis-associated tumourigenesis Article Snippet: In select experiments, mice were treated with a neutralising Bacteria:Article Title: Cross-talk between the gut microbiota and monocyte-like macrophages mediates an inflammatory response to promote colitis-associated tumourigenesis Article Snippet: In select experiments, mice were treated with a neutralising Sequencing:Article Title: Cross-talk between the gut microbiota and monocyte-like macrophages mediates an inflammatory response to promote colitis-associated tumourigenesis Article Snippet: In select experiments, mice were treated with a neutralising Derivative Assay:Article Title: Cross-talk between the gut microbiota and monocyte-like macrophages mediates an inflammatory response to promote colitis-associated tumourigenesis Article Snippet: In select experiments, mice were treated with a neutralising Functional Assay:Article Title: Cross-talk between the gut microbiota and monocyte-like macrophages mediates an inflammatory response to promote colitis-associated tumourigenesis Article Snippet: In select experiments, mice were treated with a neutralising Control:Article Title: Cross-talk between the gut microbiota and monocyte-like macrophages mediates an inflammatory response to promote colitis-associated tumourigenesis Article Snippet: In select experiments, mice were treated with a neutralising |